

**Date: May 15, 2024**

**BSE Limited**

P J Towers,  
Dalal Street,  
Mumbai – 400 001

**National Stock Exchange of India Limited**

Exchange Plaza, C-1, Block G,  
Bandra Kurla Complex,  
Bandra (E), Mumbai – 400 051

**Script Code: 543904**

**Symbol: MANKIND**

Dear Sir/ Madam,

**Subject: Clarification on news item appearing in [www.business-standard.com](http://www.business-standard.com)**

---

This is with reference to BSE letter having Ref. No. L/SURV/ONL/RV/AV/ (2024-2025)/ 7 and NSE communication on NEAPS, seeking clarification in terms of Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“**Listing Regulations**”) on the news item appearing in the Business Standard on 14<sup>th</sup> May 2024.

In this regard, the Company would like to clarify that the contents of the said article are speculative in nature and there are no events which warrant a disclosure under Regulation 30 of the Listing Regulations.

As part of the growth initiatives of the Company, the Company continues to explore opportunities for inorganic growth from time to time. The Company has always followed best practices for disclosure of material events at the appropriate time and will continue to do so, as required under the Listing Regulations.

This is for your information and necessary dissemination.

Thanking You,

Yours Faithfully,

For **Mankind Pharma Limited**

**Pradeep Chugh**  
**Company Secretary and Compliance Officer**